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Reaching for the Star: Tumor Suppressor or Oncogene? 
 
Sally B. El Sitt 
Abstract 
 
Astrocytomas are tumors occurring in young adulthood. Astrocytic tumors can be 
classified into four grades according to histologic features: grade I, grade II, grade III and 
grade IV. Malignant tumors, those of grade III and IV, are characterized by uncontrolled 
proliferation, which is known to be regulated by the family of Rho GTPases. StarD13, a GAP 
for Rho GTPases, has been described as a tumor suppressor in hepatocellular carcinoma. In 
the present study, IHC analysis on Grade I-IV brain tissues from patients showed StarD13 to 
be overexpressed in grade III and IV astrocytoma tumors when compared to grade I and II. 
However, when we mined the REMBRANDT data, we found that the mRNA levels of 
StarD13 are indeed higher in the higher grades but much lower than the normal tissues. The 
overexpression of a GFP-StarD13 construct in astrocytoma cells led to the increase in cell 
death and a decrease of cell viability. Knocking down StarD13 using siRNA led to a decrease 
in cell death and an increase in cell viability. When looking at the mechanism, we found that 
the tumor suppressor effect of StarD13 is through the inhibition of the cell cycle and not 
through the activation of apoptosis. When knocking down StarD13, we also saw an increase 
in p-ERK, uncovering a potential link between Rho GTPases and ERK activation. Our future 
interests would be to determine which Rho GTPase is responsible for this effect and to 
elucidate the direct link between the Rho GTPase and ERK.  
 
Keywords: Astrocytomas, RhoGTPases, StarD13, GAP, Tumor suppressor, GFP-StarD13, 
StarD13-siRNA.
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Chapter One 
 
INTRODUCTION 
 
 
1.1. Brain tumors: 
 
1.1.1. Occurrence: 
 
Primary malignant central nervous system (CNS) tumors account for 2% of all 
cancers with an inconsistent rate of morbidity and mortality. Malignant CNS tumors 
constitute the leading cause of death from solid tumors in children and the third leading 
cause of cancer-related death for adolescents and adults aged 15 to 34 years (Buckner, et 
al., 2007). More than 18000 new diagnoses of brain and nervous system cancers are 
estimated by the American Cancer Society in the United States each year leading to 
more than 12,000 deaths (Chandana, Movva, Arora, & Singh, 2008). 
 
 
 
1.1.2. Definition, Symptoms and Risk Factors: 
 
Brain tumors are defined as a collection of neoplasms and are better known as 
“intracranial neoplasms”. Most of these tumors have similar clinical presentation, 
diagnostic approach, and initial treatment (DeAngelis, 2001). Headache, nausea, 
vomiting, seizures, and altered mental functions represent the common generalized 
symptoms of a brain tumor with headache being the most common presenting symptom 
(Buckner, et al., 2007; Chandana, et al., 2008). Diet, alcohol, smoking, occupation and 
industry, infections, allergies, exposure to ionizing or nonionizing radiation, head 
trauma, family history, and inherited polymorphisms in genes related to carcinogen 
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metabolism, oxidative   metabolism, and DNA repair constitute the possible risk factors 
that have been associated with brain tumors (Wrensch, Minn, Chew, Bondy, & Berger, 
2002).  
 
 
1.1.3. Treatment: 
 
Treatment of primary brain tumors includes surgery, radiation therapy, and 
chemotherapy (Chandana, et al., 2008). Surgery represents the goal standard treatment 
of benign or potentially anaplastic brain tumors providing not only histological diagnosis 
but also radical surgical removal when feasible (Chandana, et al., 2008; Cornu, 
Dormont, Marsault, & Philippon, 1996).  For patients with metastatic brain tumors, 
epidural spinal cord compression, and leptomeningeal metastases, radiotherapy is of 
great importance prolonging the survival of most patients (Buckner, et al., 2007). 
Several trials highlighted the importance of adjuvant chemotherapy, -using nitrosoureas, 
as having the ability to cross the blood brain barrier and being lipid soluble (Stewart, 
2002). 
 
 
1.1.4. Non gliomas:  
 
CNS tumors can be either gliomas or nongliomas (Buckner, et al., 2007) (Table 
1). Nongliomas can be benign tumors, such as meningiomas and pituitary adenomas, or 
malignant tumors, such as primitive neuroectodermal tumors (medulloblastomas), 
primary CNS lymphomas (Buckner, et al., 2007). Meningiomas, originated in the dura 
that covers the brain and spinal cord, represent the second most common benign CP 
(cerebellopontine) angle tumor arising from neoplastic meningothelial cells (Buckner, et 
al., 2007; Wiemels, Wrensch, & Claus, 2010). Pituitary adenomas are defined as 
nonmetastasizing neoplasms consisting of adenohypophysial
 
cells. Some adenomas 
exhibit a slow rate of growth while some are rapidly growing tumors (Asa & Ezzat, 
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1998). Medulloblastomas, occurring in the posterior fossa, are very common in children 
representing 15–25% of all childhood primary central nervous system (CNS) neoplasms 
(Brandes, Paris, & Basso, 2003; Franceschi, et al., 2007). Primary CNS lymphomas 
account for 1% or less of all primary brain tumors (DeAngelis, 2001). The only two 
established causes of primary CNS tumors are heritable syndromes and ionizing 
radiation (Preston-Martin, 1996). Patients with a compromised immune system are at a 
higher risk for CNS lymphomas (Buckner, et al., 2007). 
 
         
Table 1: Distribution of all primary brain and CNS (central nervous system) 
tumors by histology, CBTRUS (Central Brain Tumor Registry of the United States) 
1998-2002 (N=63,698). Gliomas account for 40% of all tumors and 78% of malignant 
tumors. From CBTRUS (2005). Statistical Report: Brain Tumors in the United States, 
1998-2002. (Buckner et al. 2007). 
 
 
1.1.5. Gliomas: 
 
The diffuse infiltration of white matter tracts constitutes the primary characteristic 
of most gliomas (Buckner, et al., 2007). Gliomas comprise two major categories: 
astrocytic and oligodendroglial tumors, which can either, be low grade or high grade 
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(DeAngelis, 2001) (Table 2). Gliomas are genetically, histologically, and therapeutically 
heterogeneous and can take place anywhere in the brain but specifically affect the 
cerebral hemispheres (DeAngelis, 2001). The most common glial tumors are the 
malignant astrocytomas, the anaplastic astrocytoma and glioblastoma multiforme 
(DeAngelis, 2001). 
 
 
              
Table 2: Distribution of all primary brain and CNS (central nervous system) 
gliomas by histology subtypes, CBTRUS (Central Brain Tumor Registry of the United 
States)  1998-2002 (N=25,539). Astrocytomas and glioblastomas account for 75% of 
all gliomas. From CBTRUS (2005). Statistical Report: Brain Tumors in the United 
States, 1998-2002. (Buckner et al. 2007). 
 
 
1.2. Astrocytomas:  
 
1.2.1. Definition: 
 
Astrocytomas are tumors occurring in young adulthood defined as CNS 
neoplasms originated in astrocytes, star-shaped brain cells (Kennedy 2009). The brain 
consists of two types of cells: neurons, the basic structural unit and astrocytes, the 
supportive cells. Astrocytes provide the neurons with trophic, metabolic and structural 
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supports. The communication between the neurons and their supportive cells is mediated 
through Ca
2+
 signaling (Nag, 2011). 
 
 
1.2.2. Classification:  
 
The World Health Organization
 
(WHO) system classifies the astrocytic tumors 
into four grades: grade I (pilocytic astrocytoma), grade II (diffuse astrocytoma) with 
cytological atypia alone, grade III (anaplastic astrocytoma) showing anaplasia and 
mitotic activity in addition and grade IV (glioblastoma) presenting microvascular 
proliferation and/or necrosis (Louis, Ohgaki, Wiestler, & Cavenee, 2007). Malignant 
gliomas are those of grade III and IV (Wen & Kesari, 2008). Glioblastomas account for 
at least 80 percent of malignant gliomas (DeAngelis, 2001). 
 
 
1.2.3. Glioblastoma: 
 
Glioblastoma, the most deadly primary brain tumor, has been identified as a 
complex disease, in which many signaling pathways are disrupted mainly the epidermal 
growth factor receptor (EGFR) pathway (Bredel, et al., 2011) (Figure 1). Glioblastomas 
are divided into two subtypes based on biologic and genetic differences: primary 
glioblastomas occurring de novo in patients older than 50 years and secondary 
glioblastomas developing in younger patients through the progression from low-grade or 
anaplastic astrocytomas (Watanabe, et al., 1996; Wen & Kesari, 2008). High rate of 
overexpression or mutation of the epidermal growth factor receptor, p16 deletions, and 
mutations in the gene for phosphatase and tensin homologues (PTEN) characterize 
primary glioblastomas whereas secondary glioblastomas involve mutations in the
 
p53 
tumor-suppressor gene and overexpression of the platelet-derived
 
growth factor receptor 
(PDGFR), abnormalities in the p16 and
 
retinoblastoma (Rb) pathways (DeAngelis, 2001; 
Wen & Kesari, 2008). 
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Fig 1: MRI of a Glioblastoma Multiforme in the Left Frontal Lobe,                   
Obtained after the Administration of Gadolinium. The tumor is characterized by the 
irregular enhancing margin with central necrosis (DeAngelis 2001). 
 
 
1.3. Rho GTPAses: 
 
1.3.1. Definition: 
 
Rho GTPases are known to be involved in the stimulation of cell cycle 
progression. The family of Rho GTPases contains 20 small G proteins playing important 
roles in the regulation of the cytoskeleton, the cell cycle, the cell migration and the cell 
polarity (Karlsson, Pedersen, Wang, & Brakebusch, 2009) (Figure 2). Rho GTPases are 
guanine nucleotide binding proteins existing in two forms: the active form which is GTP 
bound and the inactive one that being GDP bound and it is important to note that only in 
the active form, Rho GTPases can interact with other effectors mediating their cellular 
functions (Boettner & Van Aelst, 2002). Rho GTPases act as molecular switches in 
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many important mechanisms: actin polymerization, cell adhesion, and gene transcription 
(Ridley, 2001). The family of these proteins comprises many types of effectors including 
actin nucleation promoting molecules such as N-WASP and WAVE, kinases e.g. 
PAK1–6, MRCKα/β, ROKα/β, adaptors e.g. IQGAP1/2, Par6 and other protein families. 
The most important studied members of the Rho family are Rac 1(Ras-related C3 
botulinum toxin substrate 1), Cdc42 (cell division cycle 42) and Rho A (Ras 
homologous member A) (Boettner & Van Aelst, 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Delineation and structure of the Rho family. Proteins considered so far 
as Rho members were aligned with GTPases of other Ras-like families, and the 
unrooted tree was obtained by NJ (ClustalX). Only the Rho domains, corresponding 
to amino acids 5–173 of Rac1, were used for the alignment. Structuration into 4 
clusters and 8 subfamilies is figured by light and dark gray ellipses, respectively. 
(Boureux et al. 2007). 
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1.3.2. Rac1: 
 
Rac1 is a small GTP-binding protein belonging to the Rho subfamily of Ras-
related protein involved in the regulation of cell morphology and growth. Rac1 acts also 
as a regulator of many cellular activities such as regulation of gene expression, actin 
cytoskeketal organization, regulation of cell proliferation and stimulation of cellular 
transformation and it plays a role in tumorigenesis and metastatic potential (Hwang, et 
al., 2004).  
 
 
1.3.3. Cdc42:  
 
Cdc42 is involved in the regulation of eukaryotic cell polarity important for cell 
migration and cell division because of its impact on the cytoskeleton (Johnson, 1999). 
Overexpression of Cdc42 in breast tumor and testicular cancer shows the correlation 
between the Cdc42 gene expression and tumor progression (Karlsson, et al., 2009). An 
important feature of Cdc42 is the well defined binding domain CRIB (Cdc42/Rac 
interactive domain) found in many effectors downstream of Cdc42 and Rac (Burbelo, 
Drechsel, & Hall, 1995). Cdc42 can be found in the cytoplasm or bound to the plasma 
membrane (Ziman et al. 1993).  
 
1.3.4. RhoA: 
 
RhoA can exist either in the cytoplasm or at the plasma membrane (Adamson, 
Paterson, & Hall, 1992). Overexpression of RhoA is found in many human tumors such 
as skin, liver and colon cancer (Karlsson, et al., 2009). Rho A is required to assemble 
stress fibers and to preserve cell adhesion. Nowadays it is evident that RhoA is tightly 
associated to the attainment of migratory and metastatic phenotypes and it is involved 
in an α6β4 integrin-mediated pathway leading to the formation of lamellipodia and 
migration in colon carcinoma cells and in the invasion of epithelial or hepatoma cell 
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lines. Moreover, RhoA is a major component of focal complexes, actin-rich cell surface 
structures located at the leading edge of lamellipodia (Abecassis, Olofsson, Schmid, 
Zalcman, & Karniguian, 2003).  
 
 
1.3.5. Rho GTPases in cancer:  
 
In cancer cells, alterations in signaling pathways render the cells defective in 
recognizing the normal environmental signals responsible for controlling cell 
proliferation, apoptosis, and differentiation (Alberts, et al., 2008). The rate of cell 
proliferation and the rate of cell apoptosis determine the ability of tumor cell 
populations to expand in number (Hanahan & Weinberg, 2000). Malignant tumors 
show several features including uncontrolled proliferation, enhanced migration 
properties, loss of epithelial cell polarity, and altered interactions with neighboring cells 
and the surrounding extracellular matrix. Genetic screens of many human cancers have 
revealed altered expression of various Rho family GTPases (Ridley, 2004). RhoC 
mRNA level is increased in metastatic melanomas and Rac3 activity is increased in 
highly proliferative breast cancer cell lines (Ridley, 2004). Regulators of Rho GTPases 
also show aberrant expression in human tumors, including Vav1 in neuroblastomas 
(Hornstein et al. 2003). A comparison of the gene expression pattern in a metastatic 
breast cancer cell line compared to its non-metastatic counterpart revealed that many 
genes encoding actin regulatory proteins are more highly expressed in metastatic cells 
(Wang, et al., 2002). All of these processes are regulated by the proteins of the Rho 
GTPase family making them with their regulators and effectors important in controlling 
tumor formation and progression in humans (Karlsson, et al., 2009). 
The amount of Rho GTPases, in particular RhoA, has been shown to be frequently 
increased in different types of cancers suggesting the role of this family of proteins in 
human carcinogenesis (Fritz, Gnad, & Kaina, 1999). The Rho proteins implicated in 
many biological processes such as cell adhesion, migration, transcriptional activation, 
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cell-cycle progression are known for their important role in the formation and 
progression of tumors in vivo (Malliri & Collard, 2003).   
 
 
1.3.6. Regulation of Rho GTPases: 
 
The regulation of Rho GTPases is governed by three classes of regulatory 
proteins: GAP (GTPase activating proteins), GEF (guanine nucleotide exchange 
factors), which accelerate the very slow intrinsic guanine nucleotide exchange and GTP 
hydrolysis activity, and GDI (guanine nucleotide dissociation inhibitors) (Kawai, et al., 
2009; Kim, Vigil, Der, & Juliano, 2009) (Figure 4). In order to accomplish several 
cellular functions, Rho GTPases cycle between an active GTP-bound form and an 
inactive GDP-bound form (Kawai, et al., 2009). GEF activates Rho GTPases by 
exchanging GDP for GTP while GAP inhibits these proteins by hydrolyzing GTP to 
GDP. GDI negatively regulates the Rho family members by binding to a prenylated 
GDP-bound Rho proteins removing Rho GTPases from the plasma membrane 
(Buchsbaum, 2007; Kawai, et al., 2009). GEFs seemed to be more important in the 
context of GTPase regulation. In response to various stimuli, GEFs gets activated and 
consequently lead to the activation of GTPases which undergo a conformational change 
enabling them to interact with downstream effectors, producing a biological response. 
GAPs, to which a “secondary” role has been attributed, can now interfere to complete 
the cycle (Bernards & Settleman, 2004). The family of RhoGEFs consists of 
approximately 80 molecules in the human genome. These proteins are a part of either 
the Dbl family or the Dock family (Salhia, et al., 2008). GEFs are characterized by the 
presence of DH (Db1 homology) domain, a core catalytic domain stabilizing GTP-free 
Rho intermediates. Another domain, the PH (pleckstrin homology) domain is found in 
most DH-containing Rho family GEFs (Buchsbaum, 2007). The catalytic activity of 
DH domain is affected by the PH domain which can bind to phosphorylated 
phosphoinositides as well as proteins (Rebecchi, Crivori, Sarra, & Cocconcelli, 1998). 
The PH domain promotes the localization of GEFs by interacting with PIP3 (Zheng, et 
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al., 1996). PI3K (phosphatidylinositol 3-kinase) activation leads to the production of 
PIP3 that binds to the PH domain of GEFs and contributes to their localization 
(Raftopoulou & Hall, 2004). 
 
	 
Figure 3: The regulation of Rho GTPases by GAPs, GEFs and GDIs. RhoGEFs 
activate the RhoGTPases by promoting the GTP nucleotide exchange. GAPs inactivate 
Rho GTPases by stimulating the intrinsic GTPase activity leading to the GDP-bound 
inactive form of Rho. Rho GTPases are kept inactive by being sequestered by GDIs in 
the cytosol. (El-Sibai). 
 
 
1.4. RhoGAPs:  
 
GAPs belong to a specific family of GTPases that accelerate the rate of GTP 
hydrolysis by up to 10
5
times (Rittinger, et al., 1997). Hence, a tumor suppressor role 
has been suggested for GAPs counteracting the oncogenic potential of Rho proteins 
(Yau, et al., 2009). All the members of the RhoGAP family have a conserved RhoGAP 
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domain consisting of 200 amino acids sequences with more than 20 % of these 
sequences being identical to other family members (Ahmadian, Wiesmuller, Lautwein, 
Bischoff, & Wittinghofer, 1996; Moon & Zheng, 2003). Rittinger et al. examined the 
crystal structures of few RhoGAP domains with their Rho GTPase substrates, revealing 
the topology and critical residues in the active site which participate in catalysis. Nine 
helices and a highly conserved arginine residue located in a loop structure constitute the 
structure of the RhoGAP domain (Gamblin & Smerdon, 1998). This critical arginine 
residue of the GAP is responsible for the enhancement of GTP hydrolysis by stabilizing 
the transition state of the substrate
 
binding site of the small GTPase (Moskwa, Paclet, 
Dagher, & Ligeti, 2005). The C-terminus of RhoGAP includes a GAP domain of more 
than 140 amino acids (Lamarche & Hall, 1994). Rho/RacGAPs include a wide variety 
of domains that possibly interact with proteins and lipids in addition to the GAP 
domain. This interaction can change the activity, the localization, or the substrate 
specificity of the relevant GAP (Moskwa, et al., 2005). Examples of such domains are: 
PDZ, SH2, SH3, and SEC14 which are involved in protein-protein interactions, 
membrane targeting, and cellular localization. RhoGAPs can contain from one to nine 
domains (Kandpal, 2006). GAPs have captured the attention because about 0.5 % of all 
predicted human genes encode likely GAPs making them important in GTPase 
regulation (Bernards & Settleman, 2004). RhoGAPs are overabundant; their number 
exceeds the number of the Rho GTPases by 2- to 3-fold (Kim, et al., 2009; Lamarche & 
Hall, 1994; Tcherkezian & Lamarche-Vane, 2007) (Figure 3). Several possible 
explanations have been proposed to answer this issue including the fact that some 
GAPs are specific for a single Rho-GTPase or a specific Rho-GTPase pathway, while 
others are expressed preferentially in certain types of tissues and show tissue-specific 
functions. Moreover, Rho-GAPs have been shown to act as effectors or scaffold 
proteins through their GAP domain which functions as a recognition site in this case 
(Tcherkezian & Lamarche-Vane, 2007). In addition to their role as negative regulators 
of the Rho GTPases, RhoGAPs are involved in specific biological functions such as 
exocytosis, endocytosis, cell migration and cytokinesis (Grogg & Zheng 2010). Several 
mechanisms, including protein–protein interactions, phospholipid interactions, 
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phosphorylation, subcellular translocation and proteolytic degradation are responsible 
for the regulation of GAP activity (Bernards & Settleman, 2004). 
 
 
         
Figure 4: Phylogenic tree of the RhoGAP family from yeast to human. An 
unrooted tree based on sequence homology of the conserved RhoGAP domain. The 
RhoGAP domains of 73 characterized GAPs were aligned with the ClustalW program 
and the phylogenic tree was generated with the Phylodraw program. (Tcherkezian & 
Lamarche-Vane, 2007). 
 
 
 
 
 
  
 14 
 
1.4.1. The DLC family:  
 
Garrett et al. identified the first RhoGAP (Tcherkezian & Lamarche-Vane, 2007). 
Since that time more than 50 RhoGAPs in the human genome were characterized, three 
of which contain START domain: DLC1, DLC2 known also as START-GAP2 or 
StarD13 and DLC3 (Soccio & Breslow, 2003). The three DLC proteins are 
characterized by the presence of three motifs: a sterile α motif (SAM), a RhoGAP 
catalytic domain, and a START (Star-related lipid transfer) domain (Qian, et al., 2007). 
The SAM domain consists of about 70 residues and has been shown to play several 
roles particularly as protein interaction modules because of its ability to interact with 
other SAM domains (Li, et al., 2007). SAM domains are located on the N-terminus and 
may bind to DNA or RNA (Liao & Lo, 2008). DLC2-SAM shows only 15-30% 
homology with other SAM domains and is considered as the prototype in the family of 
the DLC2-related proteins (Li, et al., 2007). The structure of DLC2-SAM domain has 
been revealed by nuclear magnetic resonance (NMR) methods that showed an anti-
parallel four-helix bundle (Kwan & Donaldson, 2007).  RhoGAP domains switch off 
Rho GTPases by converting the active GTP-bound Rho proteins to the inactive GDP-
bound state (Liao & Lo, 2008). Star-related lipid transfer (START) domains consist of 
about 210 amino
 
acid lipid binding domains involved in lipid metabolism, lipid 
transport, and cell signaling events. The DLC family has been established as tumor 
suppressor genes although little is known about their mechanism of action. The 
RhoGAP activity is needed for DLC-dependent tumor suppressor activity (Qian, et al., 
2007). 
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1.4.2. StarD13:  
 
When searching for additional candidate tumor suppressor loci critical in 
hepatocellular carcinoma after the well-known and established tumor suppressor genes 
p53, c-myc, p16
ink4
 and β-catenin, Ching et al. identifies a novel gene DLC2 on 
chromosome 13q12 which was found to be underexpressed in hepatocellular carcinoma 
(Ching, et al., 2003; Ng, et al., 2006). DLC2 which is also known as steroidogenic acute 
regulatory protein-related lipid transfer (START) domain containing protein 13 
(StarD13), display high level of homology with DLC1 (deleted in liver cancer 1), a 
gene coding for a Rho GTPase activating protein. These two proteins have 51% identity 
and 64% similarity at the level of their amino acid sequences sharing the same SAM-
RhoGAP-START domain organization (Ng, et al., 2006; Ullmannova & Popescu, 
2006) (Figure 5A). DLC1 has been described as a tumor suppressor acting as a GTPase 
activating protein (GAP) for members of the Rho GTPase family, mainly RhoA-C and 
Cdc42 involved in cell migration and regulation of the cytoskeleton (Kim, et al., 2009). 
DLC1 is down-regulated in many types of cancers including lung, breast, prostate, 
kidney, colon, uterus, ovary, and stomach due to two major causes: genomic deletion 
and promoter hypermethylation. DLC1 is involved in the regulation of actin 
cytoskeleton, cell shape, attachment, migration, proliferation, focal adhesion formation, 
cell survival, and induction of apoptosis (Liao & Lo, 2008; Lin, et al., 2010).  
 
Similar to DLC1, DLC2 is down-regulated in several types of cancer including lung, 
ovarian, renal, breast, uterine, gastric, colon and rectal tumors (Ullmannova & Popescu, 
2006). Through its RhoGAP activity, the DLC2 protein acts on RhoA-C and Cdc42 but 
not on Rac1 (Ching, et al., 2003; Kawai, et al., 2009; Leung, et al., 2005). An 
established effect of DLC2 GAP domain overexpression is the inhibition of the Rho-
mediated formation
 
of actin stress fibers (Ching, et al., 2003). The StarD13 also inhibits 
Ras signaling and Ras-induced cellular transformation in a GAP-dependent manner 
(Ching, et al., 2003; Kawai, et al., 2009; Ng, et al., 2006). START-GAP2 is found to be 
located in focal adhesions. The interaction between FAT (focal adhesion targeting) 
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domain, which consists of amino acid residues present on the 318–472 position in the 
N-terminal region, and tensin2, one of focal adhesion components, is responsible for the 
localization of DLC2 in focal adhesions (Kawai, et al., 2009). Xiaorong et al. reported 
significant correlations between underexpression of DLC2 and cell differentiation. In 
addition, a negative correlation was established between DLC2 and RhoA. DLC2 
seemed to inhibit hepatocarcinogenesis by suppressing RhoA activity (Xiaorong, Wei, 
Liyuan, & Kaiyan, 2008). On the other hand; a study conducted by Yau et al. 
investigated the role of DLC2 by generating DLC2-deficient mice. The mice that were 
defective in DLC2 were able to survive to adulthood unlike the knockout of DLC1 
which led to embryonic lethality. These findings suggest that DLC1 might be able to 
compensate the functions of DLC2 in embryonic development. The DLC2-deficient 
mouse has emerged as an important tool to study the function of DLC2 in other types of 
cancer (Yau, et al., 2009). 
 
In addition to the RhoGAP domain, the START domain plays an important role by 
targeting the tumor suppressor DLC2 to mitochondria in tight association with lipid 
droplets, which are defined as a reservoir of lipids implicated in the synthesis and 
maintenance of membranes. This indicates a possible role of DLC2 in lipid transport 
and in the regulation of the mitochondrial pathway of apoptosis and mitochondrial 
membrane permeability (Ng, et al., 2006). 
 
The tumor suppressor StarD13 possesses four isoforms: DLC2α, DLC2β, DLC2γ, and 
DLC2δ (Figure 5B). DLC2α and DLC2β, containing the full SAM-RhoGAP-START 
domain organization, showed only differences in few amino acids at the N-terminus. 
DLC2γ has two domains instead of three: RhoGAP and START domains while DLC2δ 
has only the SAM domain (Leung, et al., 2005; Li, et al., 2007). The study conducted 
by Leung et al. characterized two amino acids K618E and R622E that are critical for 
the RhoGAP activity of DLC2. 
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Another study conducted by Leung reported that the deleted in liver cancer 2 suppresses 
cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway through 
its RhoGAP function. ERK1/2 pathway is known to be required for the development of 
cancer cell characteristics from uncontrolled cell growth to increased cell motility and 
cell invasion (Leung, et al., 2010).   
 
          
 
Figure 5: A. The StarD13 protein domains:  
a) A sterile ɑ  motif (SAM) 
b) A RhoGAP catalytic domain 
c) A START (Star-related lipid transfer) domain 
B. The four isoforms of StarD13 (DLC2α,β,γ,δ).  
(Atlas of Genetics and Cytogenetics in Oncology and Haematology) 
 
 
1.5. The ERK1/2 signalling pathway:  
 
Growth factors are known for their ability to promote cell survival and 
proliferation (Boucher et al., 2000). Many of these growth factors once they stimulate 
their receptors, activate extracellular signal-regulated kinases, ERKs, also known as 
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MAP kinases (De Vries-Smits et al., 1992). MAPK (Mitogen-activated protein kinase) 
pathways are defined as evolutionarily conserved kinase modules linking extracellular 
signals to the machinery that controls fundamental cellular processes such as 
proliferation,growth, differentiation, apoptosis and migration (Dhillon et al., 2007). 
Among the six distinct groups of MAPKs  that have been characterized in mammals; 
extracellular signal-regulated kinase (ERK)1/2, ERK3/4, ERK5, ERK7/8, Jun N-
terminal kinase (JNK)1/2/3 and the p38 isoforms α/β/γ(ERK6)/γ, the ERK pathway, 
which is deregulated in one-third of all human cancers, is the best studied (Dhillon et 
al., 2007). ERKs (MAP kinases) get activated by phosphorylation by MAPKKs 
(MAP kinase kinases) which are activated by MAPKKKs (MAP kinase kinase 
kinases) (Peyssonnaux & Eychène 2001). Several studies reported the implication of 
Rho proteins in the regulation of ERK1/2; Rho proteins act by determining the 
magnitude or duration of ERK1/2 activation in response to RAS activation induced by 
either growth-factor stimulation or oncogenic mutation (Sahai & Marshall 2002).  
 
 
1.6. Purpose of our study: 
 
Our laboratory has an interest in brain tumors, particularly astrocytomas. Based 
on the newly described role of StarD13 as a tumor suppressor for hepatocellular 
carcinoma, we had an interest to test this role in astrocytomas. For this purpose, two 
approaches were used: the first one was the overexpression of StarD13 using the GFP-
StarD13 construct and the second one, the knockdown of StarD13 using siRNA. 
Following the altered expression of StarD13, the cell viability was assessed using two 
different methods: the trypan blue exclusion method and the cell proliferation reagent 
WST-1. In addition, the effect of StarD13 overexpression and knockdown on cell cycle 
and apoptosis was determined using flow cytometry and annexin V binding assays. In 
order to understand the mechanism of action of StarD13 as a tumor suppressor, this 
study highlighted the link between StarD13 and p-ERK. This will confirm StarD13 as a 
general potent tumor suppressor and will propose a therapeutic role in many types of 
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cancers through the overexpression of this tumor suppressor, which would lead to a 
decrease in malignancy. 
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Chapter Two 
 
MATERIALS & METHODS 
 
 
2.1. Cell line and cell culture: 
The human glioma cell line T98G was maintained in DMEM containing 10% fetal 
bovine serum (FBS) and 100U penicillin/streptomycin at 37°C, 5% CO2 in a humidified 
chamber. 
 
2.2. Transfection with siRNA: 
Cells were transfected with StarD13 siRNA or with control siRNA sequences 
targeting GL2 luciferase for 72 hours prior to the day of the experiment using Hiperfect 
(Qiagen) as described by the manufacturer. StarD13 suppression of protein levels was 
analyzed by Western blotting using antibodies against total StarD13.      
 
 
2.3. Overexpression with GFP: 
Cells were transfected with GFP-StarD13 or with GFP-JB662 (control) for 24 
hours prior to the day of the experiment using Lipofectamine (Invitrogen) as described 
by the manufacturer. StarD13 overexpression was analyzed by Western blotting using 
antibodies against total StarD13. 
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2.4. Proliferation: 
Depending on the type of experiment, cells were seeded either in 12 well plate or 
in 96 well plate. After 24 h of seeding, cells were transfected with StarD13 siRNA or 
overexpressed with GFP-StarD13. At the end of each treatment period, cell viability 
was determined using two methods: 
 
Trypan blue exclusion method: 10 μL of cells were mixed with 10 μL of trypan blue. 
Dead cells appear blue, whereas living cells exclude trypan blue and appear bright. The 
percent viability was determined by visually counting the dark cells compared with the 
live bright cells. 
 
Cell Proliferation Reagent (WST-1; Roche, Mannheim, Germany). At the end of 
the treatment period, water-soluble tetrazolim salt (WST-1 was added to the cells and 
kept in a humidified incubator (37°C) at 95% air and 5% CO2 for 4 hours. WST-1 is a 
tetrazolium salt that, when in contact with metabolically active cells, gets cleaved to 
formazan by mitochondrial dehydrogenases. The formazan dye was then measured 
colorimetrically at 450 nm. The results were expressed as percent of control.  
 
 
2.5. Pull down assays:  
 
Cells were lysed and incubated with GST-CRIB or GST-RBD and the pull-down 
assay performed using the RhoA/Rac1/Cdc42 Activation Assay Combo Kit (Cell 
BioLabs) following the manufacturer’s instructions. GTP-RhoA, GTP-Rac1 or GTP-
Cdc42 was detected by western blotting using the anti-RhoA, anti-Rac1 or anti-Cdc42 
antibodies provided in the kit.  
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2.6. Flow cytometry:  
 
Cells were seeded in 6 well plate and after 24 hours transfected with StarD13 
siRNA or with GFP-Star. Treated cells were placed into 15 mL Falcon tubes and 
centrifuged at 1500 rpm for 5 minutes. The pellet was then washed by resuspending it 
in 1 mL of ice-cold 1x phosphate buffered saline (PBS). Cells were centrifuged again 
under the same conditions as before and resuspended in 1 mL ice cold 1x PBS followed 
by 4 mL of 70% ethanol and stored at -20°C for a few days. Later, cells were thawed 
and centrifuged at 1500 rpm for 5 minutes, washed with 1 mL ice-cold 1x PBS, 
centrifuged again, and then treated with 100 μL of RNase and incubated for an hour at 
37°C. The cells were then pelleted at 2000 rpm for 5 minutes, and the pellets were 
washed with 500 μL of 1x PBS, transferred to labeled 6 mL polystyrene round bottom 
falcon tube, and stained with 30 μL propidium iodide for 10 minutes in the dark. Cells 
were analyzed using a FACScan, which indicated the distribution of the cells into their 
respective cell cycle phases based on their DNA content. G0/G1 cells were 2n; S-phase 
cells were >2n but <4n while G2/M were 4n. Cell DNA content was determined by 
CellQuest software. An increase in cells in the pre-G1 phase is indicative of an increase 
in apoptosis. The ratio of cells in the pre-G1 phase was compared with those of the 
control. 
 
 
2.7. Western Blotting:  
 
Protein lysates were prepared by lysing cells in lysis buffer. Protein samples were 
separated by SDS-PAGE on 8% or 12% gels and transferred to nitrocellulose 
membranes. After they were blocked with 5% non fat dry milk in PBS containing 0.1% 
Tween-20 for 1 h at room temperature, the membranes were incubated with primary 
antibody (Goat polyclonal anti-StarD13 antibody obtained from Santa Cruz). After 
washing, the membranes were incubated with secondary antibody. Then the membranes 
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were washed and treated with western blotting chemiluminescent reagent to visualize 
the bands, the results were obtained on Kodak film. 
 
 
2.8. Immunohistochemistry:  
 
Frozen human astrocytoma tissues of grades I and IV were sectioned to 8 μm 
sections using a refrigerated microtome. Tissues were fixed with 4% paraformaldehyde 
for 10 minutes, and permeabilized with 0.5% Triton-X100 for 10 minutes. To decrease 
background fluorescence, tissues were rinsed with 0.1M glycine then incubated with 
0.1M glycine for 10 minutes. For blocking, tissues were incubated 4 times with 1% 
BSA, 1% FBS in PBS for 5 minutes. Samples were stained with StarD13 primary 
antibody for 2 hours and with a fluorophore-conjugated secondary antibody for 2 hours. 
Tissue fluorescent images were taken using a 10X objective on a confocal microscope. 
For image analysis, all digital images were imported in image J software (National 
Institutes of Health, MA). The total fluorescence intensity of a fixed area from at least 
10 different frames from each tissue was determined.  
 
2.9. Annexin Staining:  
 
Cells were seeded at a density of 1x 10
6
 cells/mL. After 24 h of seeding, cells were 
transfected with either control siRNA or StarD13 siRNA and incubated for 72h. At the 
end of the incubation period, cells were trypsinized and centrifuged at 1500 rpm for 5 
minutes. The pellet was then washed by resuspending it in 1 mL of ice-phosphate 
buffered saline (PBS). Cells were centrifuged again under the same conditions as 
before. Cells were then stained with 5μL of Annexin V FITC and 10 μL of Propidium 
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Iodide cells and incubated at room temperature for 10 minutes and protected from light. 
The fluorescence of the cells was determined immediately with a flow cytometer. Cells, 
which are early in the apoptotic process, will stain with the Annexin V FITC Conjugate 
alone. Live cells will show no staining by either the Propidium Iodide Solution or 
Annexin V FITC Conjugate. Necrotic cells will be stained by both the Propidium 
Iodide Solution and Annexin V FITC Conjugate.  
 
2.10. REMBRANDT database:  
To determine the expression of StarD13 in human gliomas, we mined the 
publicly available Repository for Molecular Brain Neoplasia Data (REMBRANDT) 
gene expression microarray database containing 452 clinically annotated brain tumor 
specimens (National Cancer Institute, 2005; REMBRANDT home page: 
<http://rembrandt.nci.nih.gov>; accessed December 20, 2010). We specifically 
examined the gene expression data from nonneoplastic brain (NB, n = 28), low-grade 
astrocytomas (LGGs, n = 148), and glioblastoma multiformes (GBMs, n = 226). 
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Chapter Three 
 
RESULTS 
 
 
3.1. StarD13 is a GAP for RhoA and Cdc42 not for Rac1: 
 
In order to study the role of StarD13 in astrocytoma malignancy, we started by 
verifying that StarD13 is a GAP for RhoA and Cdc42 and not for Rac1. This was 
achieved by studying the activation of the three Rho GTPases in T98 cells following 
the transfection by GFP-StarD13. Using a GST-CRIB pull down assay, we found that 
the levels of the active RhoA and the active Cdc42 were lower in cells transfected 
with GFP-StarD13 (Figure 6 A and B) as compared to the controls. On the other 
hand, the overexpression of StarD13 did not affect the active Rac1 (Figure 6C). This 
confirmed that StarD13 is a specific GAP for Rho and Cdc42. 
 
 
3.2. StarD13 is underexpressed in astrocytoma: 
 
Then we wanted to investigate the expression levels of StarD13 in astrocytoma 
malignancy using immunohistochemistry. Tissues of grade I and IV were stained with 
anti-StarD13 antibody (Figure 7A) and the intensity of the signal was measured using 
image J software. Our results showed that there was around 30% increase in the 
expression of StarD13 in grade IV tumors as compared to grade I (Figure 7B).  
 
 
 
  
 26 
 
3.3. StarD13 overexpression reduces cell viability: 
 
In order to determine the role of StarD13 in cell viability, we transfected T98 cells 
with GFP-StarD13 and studied the effect of this overexpression on cell viability using 
two methods: the trypan blue exclusion method and the Cell Proliferation Reagent 
(WST-1). 
 
The overexpression was apparent looking at the GFP channel and through the effect 
of over expressing GFP-StaD13 on stress fiber formation (due to Rho inhibition) as 
revealed by Rhodamine Phalloidin staining (Figure 8D). This is compared to cells 
transfected with GFP alone (Figure 8D, upper panels) where stress fibers were not 
affected. The overexpression of StarD13 decreased the percentage of live cells from 
97% to 92% (Figure 8A). This was consistent with the results of the WST-1 which 
showed a decrease of approximately 20% in cell viability (Figure 8C). 
 
 
3.4. StarD13 knockdown increases cell viability: 
 
To confirm the previous results, we knocked down expression of StarD13 with 
siRNA.  StarD13 expression was reduced by 50% as compared to cells transfected 
with control siRNA duplexes (Figure 9D). The percentage of live cells in StarD13-
siRNA treated cells was increased as compared to control-siRNA treated cells (Figure 
9A). These results were consistent with those of the WST-1 which showed an 
increase of about 30% in cell viability (Figure 9C). 
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3.5. StarD13 is overexpressed in glioblastoma according to Rembrandt results:  
 
Our immunochemistry results suggested StarD13 might be an oncogene and not a 
tumor suppressor, as the literature suggested, since StarD13 looked to be 
overexpressed in grade IV astrocytoma, as compared to grade I. However over 
expressing and knocking down StarD13 led to a decrease and increase in cell 
proliferation, respectively, as would be expected of a tumor suppressor. In order to 
reconcile our results, we mined the Rembrandt (Repository of Molecular Brain 
Neoplasia Data) database which hosts diverse types of molecular research and clinical 
trials data related to brain cancers, including gliomas. The results showed StarD13 is 
underexpressed in tumor tissues as compared to non-tumor tissues. However, if we 
compare the expression level in GBM (glioblastoma) which is grade IV astrocytoma 
to lower grade tumors, we find that the levels of StarD13 mRNA in grade IV is higher 
(Figure 10). This was consistent with our IHC results. 
 
 
 
3.6. StarD13 does not affect the apoptosis: 
 
The effect of StarD13 on cell viability could be through inducing apoptosis.  To 
study the effect of StarD13 on apoptosis, cells were stained with Annexin V FITC. 
The fluorescence was immediately measured by a flow cytometry. Cells, which are 
early in the apoptotic process, will stain with the Annexin V FITC Conjugate alone. 
Live cells will show no staining by either the Propidium Iodide solution or Annexin V 
FITC conjugate. Necrotic cells will be stained by both the Propidium Iodide solution 
and Annexin V FITC conjugate. Our results showed that the knockdown of StarD13 
did not affect the apoptosis. The percentage of apoptotic cells was not significantly 
different between the controls and the transfected cells (Figure 11 and Table). 
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3.7. StarD13 affects the cell cycle: 
 
In order to understand the mechanism through which StarD13 is affecting cell 
viability, we went on analyzing the effect of StarD13 knockdown on the cell cycle. 
This was achieved using flow cytometry. Our results showed an increase in the 
percentage of cells in the S/G2 phase as compared to the cells in the G0 phase (Figure 
12). This showed that knocking down StarD13 led to an increase in cycling cells, 
meaning StarD13 plays the role of a tumor suppressor inhibiting the cell cycle.   
 
 
3.8. ERK is downstream effector from StarD13: 
 
In order to determine the mechanism of action of StarD13, we knocked it down 
and looked at its effect on p-ERK, the extracellular signal-regulated kinase. The 
western blot showed an increase in pERK levels in siRNA-StarD13 transfected cells 
as compared to control non transfected cells (Figure 13). 
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Figure 6. StardD13 is a specific GAP for Rho and Cdc42. T98G cells were 
transfected with either GFP alone (right lanes) or with GFP-StarD13 (left lanes). 
The cells were then lyzed and incubated with A) GST-RBD (Rhotekin binding 
domain), or with B) GST-CRIB (Cdc42 and Rac interactive binding domain) to pull 
down active Rho or Cdc42 and Rac, respectively. The samples were then blotted 
with Rho, Cdc42 and Rac antibodies. The lower gels in each panel are western blots 
for the total cell lysates for loading control.   
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Figure 7: StarD13 is overexpressed in Grade IV astrocytoma compared to grade 
I. Immunohistochemistry for tumor tissues of grades I, and IV that were obtained 
from patients diagnosed with glioblastoma. A) representative micrographs of tissues 
that were stained with DAPI (middle panels) or with anti-StarD13 (left panels). B) 
The intensity of the signal was measured using ImageJ software and expressed as fold 
increase to grade I. the data is the mean -/+ SEM.  
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Figure 8: StarD13 overexpression decreased cell viability. Cells were either 
transfected with GFP alone or with GFP-StarD13. Cell viability was then determined 
using the Trypan blue exclusion method (A and B) or the WST-1 cell proliferation 
reagent (C). A and B) The results were expressed as percent of total number of cells. 
C) Results were expressed as fold increase from control (GFP alone). Data is the 
mean -/+ SEM. D) Cell were transfected with GFP alone (upper panel) or GFP-
StarD13 (lower panel) and stained with Rhodamine Phalloidin.          
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Figure 9: StarD13 underexpression increases cell viability. Cells were either 
transfected with Luciferase control siRNA or with StarD13 siRNA. Cell viability was 
then determined using the Trypan blue exclusion method A) and B) or the WST-1 cell 
proliferation reagent (C). A and B) The results were expressed as percent of total 
number of cells. C) Results were expressed as fold increase from control (luciferase). 
Data is the mean -/+ SEM. D) western blot showing the decrease in StarD13 
expression compared to actin, lower panel) in cells transfected with StarD13 siRNA 
compared to luciferase control (left lane).    
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Figure 10. StarD13 is underexpressed in glioma as compared to normal tissues. 
Data analyzed from Rembrandt website. mRNA from 28 non-tumor patient tissues, 
148 astrocytoma tissues (grade I-III) and 226 grade IV astrocytomas were quantified 
for expression levels.  
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Figure 11: StarD13 had no significant effect on apoptosis. Cells were transfected 
with either control luciferase siRNA or with StarD13 siRNA. The cells were then 
trypsinized and stained with 5μL of Annexin V FITC and 10 μL of Propidium Iodide. 
A) The fluorescence of the cells was determined immediately with a flow cytometer. 
Cells, which are early in the apoptotic process, will stain with the Annexin V FITC 
Conjugate alone. Live cells will show no staining by either the Propidium Iodide 
solution or Annexin V FITC conjugate. Necrotic cells will be stained by both the 
Propidium Iodide solution and Annexin V FITC conjugate. B) Table summarizing the 
results shown in A.  
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Figure 12: StarD13 represses the cell cycle. Cells were transfected with luciferase or 
StarD13 siRNA and stained with 30 μL propidium iodide for 10 minutes. Cells were 
analyzed using a FACScan, which indicated the distribution of the cells into their 
respective cell cycle phases based on their DNA content. G0/G1 cells were 2n; S-
phase cells were >2n but <4n while G2/M were 4n. Cell DNA content was determined 
by CellQuest software.  
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Figure 13: StarD13 affects the cell cycle through an effect on ERK. Cells were 
transfected with luciferase (left lane) or StarD13 (right lane) siRNA, lyzed and blotted 
for p-ERK (upper gel) or actin for loading control (lower gel).
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Chapter Four 
 
        DISCUSSION 
 
In this study, we examined the role of StarD13 in astrocytoma malignancy. We 
confirmed that StarD13 is a specific GAP for Rho and Cdc42. IHC analysis showed 
that StarD13 is overexpressed in grade IV astrocytoma compared to grade I. Mining 
online databases explained this observation by StarD13 being indeed overexpressed in 
grade IV astrocytoma as compared to grade I, however StarD13 is underexpressed in 
astrocytoma (grade I and IV) as compared to normal tissues. This confirmed StarD13 as 
a potential tumor suppressor in astrocytoma. In order to directly prove that, we 
overexpressed or knocked down StarD13 and looked at the effect of cell viability, 
apoptosis and proliferation in a cell culture model. In astrocytoma cell lines, 
overexpressing StarD13 led to no effect on apoptosis but to a decrease in cell viability 
and cell proliferation as reflected by a decrease in cells in S and G2 phase. Knocking 
down StarD13 with StarD13 siRNA led to no effect on cell apoptosis but to an increase 
in cell viability and cell proliferation. Knocking down StarD13 also showed an increase 
n phosphorylated ERK. 
 
Ching et al. was the first to identify and characterize StarD13 in hepatocellular 
carcinoma (HCC). We wanted to determine the role of this RhoGAP in another tumor 
model which is astrocytoma. Ching et al. reported the function of StarD13 as a GAP for 
RhoA and Cdc42 not for Rac1. Our results demonstrated that cells overexpressing 
StarD13 possessed reduced levels of RhoA and Cdc42 activation; however, the 
activation of Rac1 was not affected. Therefore, similar to its role in HCC, StarD13 has 
a RhoGAP activity for RhoA and Cdc42 in astrocytoma.  
 
The IHC analysis on Grade I-IV brain tissues from patients showed StarD13 to be 
overexpressed in grade III and IV astrocytoma tumors when compared to grade I and II. 
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This was contradictory to other studies where the StarD13 gene was found to be down-
regulated in several types of cancer including lung, ovarian, renal, breast, uterine, 
gastric, colon and rectal tumors (Ullmannova & Popescu, 2006). These results led us to 
formulate the following hypothesis: Contrary to other tumor models, in brain 
astrocytomas, StarD13 seems to be an oncogene and not a tumor suppressor.  
 
To verify this hypothesis, we wanted to determine the effect of StarD13 altered 
expression on cell viability. The overexpression of GFP-StarD13 construct in 
astrocytoma T98 cells led to the increase in cell death and a decrease of cell viability. 
This was verified using two methods: counting with trypan blue and adding the water 
soluble tetrazolium salt WST-1. On the other hand, knocking down StarD13 using 
siRNA led to a decrease in cell death and an increase in cell viability. These data 
established the growth suppressor role of StarD13 in astrocytoma. This was consistent 
with previous results which reported the role of StarD13 as a tumor suppressor in 
several types of cancer. However, these data refuted our hypothesis and did not explain 
our IHC results. StarD13 seems to be a tumor suppressor consistently with the 
literature. 
 
To answer this issue, we mined the REMBRANDT data; we found that the mRNA 
levels of StarD13 are indeed higher in the higher grades but much lower than the 
normal tissues. Hence, our IHC results were consistent with the REMBRANDT results. 
 
It would remain of interest to establish the significance of the overexpression of 
StarD13 as the malignancy of astrocytoma increases. Another study in our lab showed 
that StarD13 is needed for astrocytoma cells to undergo motility. This might explain 
why StarD13 is overexpressed in grade IV astrocytoma compared to grade I. 
 
The effect of cell viability could be either due to decreased proliferation or increased 
apoptosis. To test which underlying mechanism was responsible for the tumor 
suppressor function of StarD13, we studied the effect of StarD13 knockdown on cell 
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cycle using flow cytometry. In StarD13 siRNA transfected cells, the percentage of cells 
at the S/G2 phase was higher than that of the control cells. And the percentage of cells 
at the G1 phase was lower. These results indicated that the deleted in liver cancer 2 
blocks the cells in the G1 phase inhibiting the cell cycle progression. This was 
consistent with a study conducted by Leung et al. which demonstrated that a stable 
expression of StarD13 caused accumulation of cells in the G1 phase leading to the 
inhibition of cell growth. 
 
In addition, our results showed that StarD13 did not induce apoptosis. This was 
reflected by the percentage of apoptotic cells which was approximately similar in the 
StarD13 siRNA transfected cells and the control cells. 
 
To examine the underlying mechanism behind the tumor suppressor role of StarD13, 
we have investigated the level of ERK phosphorylation after the silencing of StarD13. 
The results showed an increase in the level of p-ERK in the cells transfected with 
StarD13 siRNA as compared to non transfected cells. These findings were in 
accordance with the study conducted by Leung which showed that StarD13 suppresses 
cell growth via the regulation of the Raf1-ERK1/2-p70S6K signaling pathway. Since p-
ERK, the extracellular signal-regulated kinase, is involved in the regulation of cellular 
growth and proliferation of several tumor types (Zheng et al. 2003), we suggested that 
maybe our StarD13 is affecting the cell growth of tumor cells via p-ERK pathway. This 
is quite interesting since it directly link Rho or Cdc42 to the inhibition of a MAPK 
pathway.  
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Chapter 5 
 
CONCLUSION 
 
In this study, we describe for the first time the tumor suppressor effect of StarD13 in 
astrocytoma. StarD13 has increased cell death and decreased cell viability. When looking at 
the mechanism, the tumor suppressor effect of StarD13 was found to be through the 
inhibition of the cell cycle and not through the activation of apoptosis .This protein is 
underexpressed in tumors but, very interestingly, its expression level increases as the tumors 
gain more malignancy. This phenomenon requires further investigation. We also revealed 
that the tumor suppressor effect of StarD13 in astrocytoma is through the inhibition of the 
ERK pathway. Future interest would be to elucidate the link between this Rho GAP and the 
MAPK pathway.  
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